Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Rabey, J. M.
Right arrow Articles by Korczyn, A. D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Rabey, J. M.
Right arrow Articles by Korczyn, A. D.
NEUROLOGY 1995;45:432-434
© 1995 American Academy of Neurology

Low-dose Clozapine in the Treatment of Levodopa-Induced Mental Disturbances in Parkinson's Disease

J. M. Rabey, MD, T. A. Treves, MD, M. Y. Neufeld, MD, E. Orlov, MD and A. D. Korczyn, MD, MSc

Article abstract-Delusions and other manifestations of psychotic behavior are common side effects in Parkinson's disease (PD) patients chronically treated with dopaminergic drugs. Clozapine, a dibenzodiazepine derivative, is an antipsychotic drug largely devoid of extrapyramidal side effects. We evaluated the effects of low doses of clozapine on the mental and motor functions in PD patients requiring antipsychotic treatment. Twenty-seven PD patients taking dopaminergic drugs and who had psychotic behavior received clozapine at 12.5 to 75 mg/d. Fifteen patients received clozapine for 1 to 11 months (mean, 6.8 months) and seven received it for 12 to 24 months (mean, 18 months). No patient exhibited motor deterioration, and the psychotic features disappeared immediately, allowing discontinuation of clozapine after several months in 10 patients. Fifteen patients are still receiving clozapine and are free of psychiatric symptoms. The clozapine treatment was discontinued after 5 days (25 mg/d) in two patients because of somnolence. No patient developed neutropenia. Clozapine in low doses is effective in the treatment of drug-induced delusions and hallucinations in PD.

NEUROLOGY 1995;45: 432-434




This article has been cited by other articles:


Home page
 NeurologyHome page
J. Jankovic
Levodopa strengths and weaknesses
Neurology, February 1, 2002; 58(90001): S19 - 32.
[Abstract] [Full Text]

Home page
 NEJMHome page
The Parkinson Study Group
Low-Dose Clozapine for the Treatment of Drug-Induced Psychosis in Parkinson's Disease
N. Engl. J. Med., March 11, 1999; 340(10): 757 - 763.
[Abstract] [Full Text] [PDF]

Home page
 J. Neurol. Neurosurg. PsychiatryHome page
R. Inzelberg, S. Kipervasser, and A. D Korczyn
Auditory hallucinations in Parkinson's disease
J. Neurol. Neurosurg. Psychiatry, April 1, 1998; 64(4): 533 - 535.
[Abstract] [Full Text] [PDF]

Home page
 JWatch PsychiatryHome page
Clozapine Reduces Treatment-Related Parkinson's Psychosis
Journal Watch Psychiatry, June 1, 1995; 1995(601): 15 - 15.
[Full Text]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1995 by AAN Enterprises, Inc.